Loading...
Market
How will China-EU trade tensions affect Sanofi's Beijing plant by end of 2025?
2
Resolution / Starting Odds
Project halted • 25%
Project delayed • 25%
Project unaffected • 25%
Project expedited • 25%
Trade agreements, Sanofi press releases, or major news outlets
Story
Sanofi's Largest China Investment: $1.1 Billion Insulin Plant in Beijing
Dec 3, 2024, 05:43 AM
Sanofi, a French pharmaceutical company, has announced plans to invest approximately $1.1 billion (€1 billion) in establishing a new insulin production facility in Beijing, marking its largest single investment in China to date. The project, which will be Sanofi's fourth production-and-supply base in the country, comes at a time of heightened China-EU trade tensions. The investment aims to boost insulin production, aligning with China's efforts to attract foreign investment amidst global economic challenges. The agreement was formalized through a Memorandum of Understanding (MoU) signed in the Beijing Economic-Technological Development Area.
View original story
Similar markets
Worsened relations • 25%
Other • 25%
Improved relations • 25%
No change • 25%
No • 50%
Yes • 50%
Fully operational • 25%
Partially operational • 25%
Other • 25%
Not operational • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
Yes • 50%
No • 50%
More than 1500 • 25%
Less than 500 • 25%
500 to 1000 • 25%
1000 to 1500 • 25%
Increase • 25%
Remain the same • 25%
Other • 25%
Decrease • 25%
No change in policies • 25%
Other changes • 25%
More restrictive policies • 25%
Less restrictive policies • 25%
New projects initiated • 25%
Projects resume • 25%
Other impact • 25%
Projects remain curtailed • 25%